


Synsight


*High-Content Screening for
AI-based Drug Discovery*

PROBLEM

> 10 years
> \$2.5 billion




Number of drugs
per billion US\$ R&D spending




OUR SOLUTION

We build an integrated platform where
HIGH-CONTENT SCREENING meet **AI-aided DRUG DISCOVERY**




Patented MTA technology unlocks
complex biological systems:
Protein-protein Interactions

*High-Content Screening
Biophysics assays*



Deep learning extracts
proprietary data
to guide Drug Design


*Big Data
Image Classification
Artificial Neural Networks*



Computer-aided Drug Discovery
leads to **innovative molecules** as
drug candidates

*Artificial Neural Networks
Generative Adversarial Networks
Biophysics HPC Simulations*

MARKET TENDENCIES



Number of non-patent publications
with "High-Content Screening"
in title (Google Scholar; 25/01/2019)

20 300 proteins
in HUMAN

130 000 – 650 000
Protein-protein
interactions
in HUMAN

4500 druggable proteins

672 protein targets / FDA approved

Enormous &
unaddressed target
opportunity !

COMPETITORS

CRO (Contract Research Organization)
Evotec, Charles River, ...

Large facilities

Strong presence

RECURSION PHARMACEUTICALS (USA)

Strongly funded

High expertise

Synsight

Fully integrated approach
(from High-content
to AI-aided Drug Discovery)

*Patented (licensed from INSERM)
innovative technology*

In France !

*High expertise
(including Structure-Based Drug Design)*

2014 - 2018

> 830 K€ total sales revenue



From 2019

Higher competitive advantage


Drug Discovery for Pharmas

Higher Revenues

Upfront and milestones revenues

Low risk

PLAN



FOUNDERS



Cyril BAUVAIS, PhD
CEO





Guillaume BOLLOT, PhD
CSO



> 35 publications in peer reviewed international journals (5 with SYNSIGHT)

J.A.C.S
Science

Nature Materials
Angewandte Chemie
J. Med. Chem.
Nucleic Acid Research



TEAM



Cyril BAUVAIS, PhD
CEO



Guillaume BOLLOT, PhD
CSO




Pierrick CRAVEUR, PhD
AI & Structural Bioinformatics



Nicolas BABAULT, PhD
Structure-based drug design
& Cell Biology



Asaki KOBAYASHI
Biophysics



PhD, from May 2019
Cell Biology



Patrick CURMI, MD, PhD
Pdt of Evry University



Denis CARNIATO, PhD
15 y. Heading Med. Chem.
Aventis & Merck



7,5 k€



135 k€



20 k€



25 k€



PARTNERSHIPS IN PROGRESS

METABRAIN

Partnership with a partnership research organization who provide top-of-the-range preclinical research facilities

For a joined integrated offer with Synsight

4P-PHARMA

Partnership based on a co-risk co-share model, with a drug development company

To ensure the development of molecules

QWANT


Partnership with a french major player of web and artificial intelligence.

To explore world health data, to find innovative target

MOLECULAR DEVICES

Partnership with a supplier of bioanalytical measurement systems for drug discovery and life sciences.

To develop together, screening methods of tomorrow



Synsight

*High-Content Screening for
AI-based Drug Discovery*

Sup1 - Technical principle of MTA

Sup2 - Pros and Cons of MTA

Sup3 - MTA vs Other Technologies